Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 30;15(1):144.
doi: 10.1186/s13195-023-01291-w.

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

Affiliations

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

Caterina Motta et al. Alzheimers Res Ther. .

Abstract

Background: Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ)42 to detect amyloid pathology, the Aβ42/Aβ40 ratio (amyR) better estimates amyloid load, with higher specificity for Alzheimer's disease (AD). However, whether Aβ42 and amyR have different meanings and whether Aβ40 represents more than an Aβ42-corrective factor remain to be clarified. Our study aimed to compare the ability of Aβ42 and amyR to detect AD pathology in terms of p-tau/Aβ42 ratio and brain glucose metabolic patterns using fluorodeoxyglucose-positron emission tomography (FDG-PET).

Methods: CSF biomarkers were analyzed with EUROIMMUN ELISA. We included 163 patients showing pathological CSF Aβ42 and normal p-tau (A + T - = 98) or pathological p-tau levels (A + T + = 65) and 36 control subjects (A - T -). A + T - patients were further stratified into those with normal (CSFAβ42 + /amyR - = 46) and pathological amyR (CSFAβ42 + /amyR + = 52). We used two distinct cut-offs to determine pathological values of p-tau/Aβ42: (1) ≥ 0.086 and (2) ≥ 0.122. FDG-PET patterns were evaluated in a subsample of patients (n = 46) and compared to 24 controls.

Results: CSF Aβ40 levels were the lowest in A - T - and in CSFAβ42 + /amyR - , higher in CSFAβ42 + /amyR + and highest in A + T + (F = 50.75; p < 0.001), resembling CSF levels of p-tau (F = 192; p < 0.001). We found a positive association between Aβ40 and p-tau in A - T - (β = 0.58; p < 0.001), CSFAβ42 + /amyR - (β = 0.47; p < 0.001), and CSFAβ42 + /amyR + patients (β = 0.48; p < 0.001) but not in A + T + . Investigating biomarker changes as a function of amyR, we observed a weak variation in CSF p-tau (+ 2 z-scores) and Aβ40 (+ 0.8 z-scores) in the normal amyR range, becoming steeper over the pathological threshold of amyR (p-tau: + 5 z-scores, Aβ40: + 4.5 z-score). CSFAβ42 + /amyR + patients showed a significantly higher probability of having pathological p-tau/Aβ42 than CSFAβ42 + /amyR - (cut-off ≥ 0.086: OR 23.3; cut-off ≥ 0.122: OR 8.8), which however still showed pathological values of p-tau/Aβ42 in some cases (cut-off ≥ 0.086: 35.7%; cut-off ≥ 0.122: 17.3%) unlike A - T - . Accordingly, we found reduced FDG metabolism in the temporoparietal regions of CSFAβ42 + /amyR - compared to controls, and further reduction in frontal areas in CSFAβ42 + /amyR + , like in A + T + .

Conclusions: Pathological p-tau/Aβ42 and FDG hypometabolism typical of AD can be found in patients with decreased CSF Aβ42 levels alone. AmyR positivity, associated with higher Aβ40 levels, is accompanied by higher CSF p-tau and widespread FDG hypometabolism.

Keywords: Alzheimer’s disease; Amyloid beta 40; Amyloid beta 42; Amyloid beta 42/40 ratio; Cerebrospinal fluid biomarkers; Fluorodeoxyglucose-positron emission tomography; Phosphorylated-tau.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Intergroup differences of cerebrospinal fluid (CSF) biomarkers. The gray zone includes patients classified as A + T − . Dotted lines represent cut-off values used for Aβ42, p-tau, and the p-tau/Aβ42 cut-off 0.086; the dashed line represents p-tau/Aβ42 cut-off 0.122. Bold lines represent comparisons with p-values < 0.05 at the Kruskal–Wallis
Fig. 2
Fig. 2
Results of the robust locally weighted regression analysis showing changes of CSF biomarkers as a function of amyR. Values of p-tau, Aβ42, and Aβ40 are expressed as z-score standardized on the average and standard deviation of the A − T − group. The dotted line represents threshold value of pathological amyR (0.06), the dotted arrow indicates the point of change of Aβ42 from normal to pathological values. CSF, cerebrospinal fluid; amyR, Aβ42/Aβ40; A, amyloid status; T, p-tau status)
Fig. 3
Fig. 3
3D brain rendering showing significant clusters obtained in SPM when comparing A − T − vs. CSFAβ42 + /amyR − (A) and CSFAβ42 + /amyR − vs. CSFAβ42 + /amyR + (B). Color scale represents t-statistics values

Similar articles

Cited by

References

    1. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018. - DOI - PMC - PubMed
    1. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–389. doi: 10.1001/ARCHNEUROL.2008.596. - DOI - PubMed
    1. Long JM, Coble DW, Xiong C, et al. Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes. 2022. 10.1093/brain/awac250. - PMC - PubMed
    1. Baldeiras I, Santana I, Leitão MJ, et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. Alzheimers Res Ther. 2018;10(1). 10.1186/S13195-018-0362-2. - PMC - PubMed
    1. Slaets S, Le Bastard N, Martin JJ, et al. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis. 2013;36(4):759–767. doi: 10.3233/JAD-130107. - DOI - PubMed